Rare disease drugs facing questions over prices, incentives

The grand secret of the rare-disease space? That rare diseases aren't really that rare, with around one in ten Americans afflicted. But with drugs treating these conditions priced at sky-high levels, can the healthcare system shoulder the financial burden they impose? Nafeez Zawahir, MD, our VP of Scientific Strategy, weighs in on the implications of orphan drug prices and potential future dynamics.

READ THE FULL ARTICLE